에이프릴바이오

397030KOSDAQ

47.8 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment19.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 34.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

April Bio is a research and development-focused company established in 2013, leveraging human antibody production and protein half-life extension technologies to develop antibody therapeutics and sustained recombinant protein drugs. Utilizing its core HuDVFab library and SAFA platform technologies, the company focuses on developing treatments for autoimmune and inflammatory diseases, generating revenue through global licensing agreements with pharmaceutical companies under its RIPCO business model.

Number of Employees

27people

Average Salary

201.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

5.20Industry Average 1.200.0Point

4.3x industry avg (risky)

ROE

-10.39Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.27Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼92.1% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

14 totalPositive 12Neutral 2Negative 0Average Sentiment Score 79.3

Positive
에이프릴바이오, 이중타깃 siRNA 초기 전임상서 후속 개발 근거 확보
에이프릴바이오의 siRNA 치료제 APB-O-001이 초기 전임상에서 PCSK9와 APOC3 동시 억제에 성공하며 용량 기준에서 기존 치료제보다 우수한 결과를 보여 긍정적인 전망을 제공했습니다.
Positive
에이프릴바이오, 이중표적 RNAi 전임상 공개…후속 개발 속도
에이프릴바이오의 이중표적 RNAi 후보물질 초기 전임상 결과 발표로 신약 개발 진전 기대.
Positive
에이프릴바이오, RNA 치료제 전문가 영입…"siRNA 신약 사업 본격...
에이프릴바이오가 RNA 치료제 분야 전문가를 영입하여 신약 개발 역량 강화에 긍정적 영향 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 18,180Won52-week high 73,30052-week low 16,770

1-month return0.0Point

1m -34.13% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

12 totalPositive 0Neutral 12Negative 0

Neutral주주총회소집공고2026-09-07
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-09-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
Neutral주식등의대량보유상황보고서(일반)2026-08-26
Neutral투자판단관련주요경영사항 (MCB 물질이전 계약 체결 건)2026-08-21